Topic:

R&D

Latest Headlines

Latest Headlines

Novartis adopts a CRISPR-Cas9 partner and jumps into the hot new R&D field

Just weeks after Novartis and Atlas Venture announced the launch of an upstart player in the fast-emerging field of CRISPR-Cas9 gene editing, the pharma giant has stepped back up to formally hammer out a partnership development deal and throw its enormous resources behind the biotech.

NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial

Investors were thrilled by the Phase IIa clinical trial results of Neuroderm's continuously delivered Parkinson's candidates that are administered via a belt or patch pump, offering patients an alternative to traditional orally delivered levodopa, which is notorious for its fluctuating concentrations in the blood.

Illumina blazes into 2015 with plans for new California campus

Illumina has been on a diagnostics roll as of late, inking deals and posting promising numbers for its next-generation sequencing technology. Now, the company is poised for more growth in the coming year with plans for a new California facility.

Qualcomm to connect medical devices to cloud for Walgreens, Novartis

Qualcomm announced medical device-related partnerships with Walgreens and Novartis at the Consumer Electronics Show in Las Vegas. Qualcomm's contribution to the partnerships will be the cloud-based data-sharing Life2Net platform, described as a nonexclusive, interoperable system for delivering healthcare.

Third Rock-backed GBT grabs a $48M round, plots upcoming IPO

The Third Rock-launched Global Blood Therapeutics has rounded up $48 million to push into the clinic with an experimental therapy for sickle cell disease and set the stage for an IPO later this year--once they have proof-of-concept data for their drug in hand.

Med tech exits pick up in 2014, momentum to continue into 2015

Venture-backed medical device and diagnostics companies are benefiting from a groundswell of investor interest in life sciences that has been spearheaded by great biotech returns for the last several years.

A record year for biotech inspires some great expectations for 2015

Yesterday's news that Moderna raised $450 million on the back of its preclinical R&D work--on top of the $500 million it already banked--stood out as the biggest new venture round recorded for an early-stage biotech like this. But it's still just a piece of the money that's been flowing into biotech over the past year--and a likely harbinger of more good things to come in 2015.

Health devices take the stage at Consumer Electronics Show

New health devices are front and center at this week's Consumer Electronics Show, reflecting the overwhelming, ongoing convergence of medical devices with information technology as well as their ever-growing consumerization.

Evotec teams up with Ohio State on a new cancer drug

German contract researcher Evotec has paired off with Ohio State to help the school develop an in-house cancer prospect, lending its technology and expertise.

Cempra shares soar on success of a head-to-head PhIII antibiotic study

Shares of Cempra shot up more than 30% in premarket trading on Monday as investors digested news of a promising outcome for its head-to-head study of its lead antibiotic solithromycin.